Vol. 2 No. 9 (2022): September
Reimbursement Recommendations

Abrocitinib (Cibinqo)

Published September 8, 2022

Key Messages

  • CADTH recommends that Cibinqo should be reimbursed by public drug plans for the treatment of patients aged 12 years and older with refractory moderate to severe atopic dermatitis (AD), including for the relief of pruritus, if certain conditions are met.
  • Cibinqo should only be covered to treat patients who have previously tried and are refractory to, or who are ineligible or cannot tolerate, the highest tolerated dose of topical treatments for AD combined with phototherapy (where available), and at least 1 of methotrexate, cyclosporine, mycophenolate mofetil, or azathioprine.
  • Cibinqo should only be reimbursed if prescribed by a dermatologist, allergist, clinical immunologist, or pediatrician, and the cost of Cibinqo is reduced.